187 related articles for article (PubMed ID: 29771164)
61. Symptom management in patients with cancer of the female reproductive system receiving chemotherapy.
Phianmongkhol Y; Suwan N
Asian Pac J Cancer Prev; 2008; 9(4):741-5. PubMed ID: 19256770
[TBL] [Abstract][Full Text] [Related]
62. Vitamin C and the anti-obesity effect of fenfluramine.
Odumosu A; Wilson CW
Int J Vitam Nutr Res; 1979; 49(3):251-63. PubMed ID: 528154
[TBL] [Abstract][Full Text] [Related]
63. [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1375-85. PubMed ID: 1386978
[TBL] [Abstract][Full Text] [Related]
64. [Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center].
Ito T; Okubo Y; Roth A
Gan To Kagaku Ryoho; 2009 Apr; 36(4):623-6. PubMed ID: 19381036
[TBL] [Abstract][Full Text] [Related]
65. Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia.
Zin CS; Rahman NA; Ismail CR; Choy LW
Pain Pract; 2017 Jul; 17(6):774-781. PubMed ID: 27676695
[TBL] [Abstract][Full Text] [Related]
66. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
[TBL] [Abstract][Full Text] [Related]
67. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients.
Riordan HD; Casciari JJ; González MJ; Riordan NH; Miranda-Massari JR; Taylor P; Jackson JA
P R Health Sci J; 2005 Dec; 24(4):269-76. PubMed ID: 16570523
[TBL] [Abstract][Full Text] [Related]
68. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC).
Schwartzberg L; Szabo S; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
Curr Med Res Opin; 2011 Apr; 27(4):837-45. PubMed ID: 21309647
[TBL] [Abstract][Full Text] [Related]
69. Symptom Clusters Change Over Time in Women Receiving Adjuvant Chemotherapy for Breast Cancer.
Albusoul RM; Berger AM; Gay CL; Janson SL; Lee KA
J Pain Symptom Manage; 2017 May; 53(5):880-886. PubMed ID: 28062343
[TBL] [Abstract][Full Text] [Related]
70. A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Gourley C; Cassidy J; Edwards C; Samuel L; Bisset D; Camboni G; Young A; Boyle D; Jodrell D
Cancer Chemother Pharmacol; 2004 Feb; 53(2):95-101. PubMed ID: 14605864
[TBL] [Abstract][Full Text] [Related]
71. Symptom Management: The Effects of Self-Affirmation on Chemotherapy-Related Symptoms.
Yildirim M; Gulsoy H; Batmaz M; Ozgat C; Yesilbursali G; Aydin R; Ekiz S
Clin J Oncol Nurs; 2017 Feb; 21(1):E15-E22. PubMed ID: 28107336
[TBL] [Abstract][Full Text] [Related]
72. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
73. Protocol for the use of vitamin C in the treatment of cancer.
Cameron E
Med Hypotheses; 1991 Nov; 36(3):190-4. PubMed ID: 1787808
[TBL] [Abstract][Full Text] [Related]
74. Quality of life and chemotherapy-related symptoms of Turkish cancer children undergoing chemotherapy.
Arslan FT; Basbakkal Z; Kantar M
Asian Pac J Cancer Prev; 2013; 14(3):1761-8. PubMed ID: 23679270
[TBL] [Abstract][Full Text] [Related]
75. Survey on symptoms in patients receiving chemotherapy in an Italian department of oncology: a comparison between period prevalences.
Crivelli F; Perfetti E; Sartorello B; Cantele V; Ostano P; Ilardi F; Di Massimo DS; Clerico M
Support Care Cancer; 2021 Jan; 29(1):255-261. PubMed ID: 32346798
[TBL] [Abstract][Full Text] [Related]
76. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life.
Carr AC; Vissers MC; Cook JS
Front Oncol; 2014; 4():283. PubMed ID: 25360419
[TBL] [Abstract][Full Text] [Related]
77. On the receiving end. IV: Validation of quality of life indicators.
Butow P; Coates A; Dunn S; Bernhard J; Hürny C
Ann Oncol; 1991 Sep; 2(8):597-603. PubMed ID: 1793727
[TBL] [Abstract][Full Text] [Related]
78. Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?
Ichim TE; Minev B; Braciak T; Luna B; Hunninghake R; Mikirova NA; Jackson JA; Gonzalez MJ; Miranda-Massari JR; Alexandrescu DT; Dasanu CA; Bogin V; Ancans J; Stevens RB; Markosian B; Koropatnick J; Chen CS; Riordan NH
J Transl Med; 2011 Mar; 9():25. PubMed ID: 21375761
[TBL] [Abstract][Full Text] [Related]
79. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent.
Riordan NH; Riordan HD; Meng X; Li Y; Jackson JA
Med Hypotheses; 1995 Mar; 44(3):207-13. PubMed ID: 7609676
[TBL] [Abstract][Full Text] [Related]
80. Safety and tolerance of ester-C compared with regular ascorbic acid.
Gruenwald J; Graubaum HJ; Busch R; Bentley C
Adv Ther; 2006; 23(1):171-8. PubMed ID: 16644619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
